Actively Recruiting
Comparing Rina-S and Investigators Choice Chemotherapy for Platinum-Resistant Ovarian Cancer in China
Led by Genmab · Updated on 2026-11-03
82
Participants Needed
17
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well a drug called Rina-S works compared to standard chemotherapy treatments for women with platinum-resistant ovarian cancer in China. This Phase 3 study focuses on patients who have ovarian, primary peritoneal, or fallopian tube cancer that does not respond well to platinum-based chemotherapy. The study aims to compare Rina-S against chemotherapy drugs already approved and used for this condition, providing important data on treatment options for this difficult-to-treat cancer. Participants will receive either Rina-S or one of four approved chemotherapy drugs Paclitaxel, Topotecan, Pegylated liposomal doxorubicin PLD, or Gemcitabine. Treatments are given through intravenous infusions. Participants have an equal chance of receiving Rina-S or the investigators choice of chemotherapy. The study does not include any placebo treatments and is an extension of a previous study. Treatment will continue as assigned, and researchers will monitor participants closely. During the trial, participants will undergo regular assessments to monitor cancer progression and treatment effects, including scans and laboratory tests. Researchers will track progression-free survival up to about 16 months and other outcomes like overall survival, response rates, quality of life, and adverse events for up to approximately 25 months. The study involves ongoing monitoring to understand the impact of treatments over time, with participation lasting up to nearly three years from the start date.
CONDITIONS
Brief Title
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Research Team
G
Genmab Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here